Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV Dalbavancin Clear all
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT03233438
View directory record Official record
Conditions
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Interventions
Dalbavancin, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 10, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

NCT03091439
View directory record Official record
Conditions
Osteomyelitis
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients

NCT02940730
View directory record Official record
Conditions
Infectious Peritonitis
Interventions
Dalbavancin via Intravenous Administration, Dalbavancin via Intraperitoneal Administration
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02961764
View directory record Official record
Conditions
Acute Bacterial Skin and Skin Structure Infections
Interventions
Usual Care, Dalbavancin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Phoenix, Arizona • Sylmar, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 10, 2026, 12:09 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

NCT03148756
View directory record Official record
Conditions
Endocarditis, Bacteremia
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 10, 2026, 12:09 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis

NCT06266494
View directory record Official record
Conditions
Frostbite
Interventions
Long-Acting silver dressings, Aloe Vera, Dalbavancin
Device · Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01339091
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Vancomycin / Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
55
States / cities
Anaheim, California • Azusa, California • Bellflower, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
Dalbavancin, Dalbavancin-matching Placebo
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
25
States / cities
Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 10, 2026, 12:09 PM EDT
Withdrawn Phase 3 Interventional

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

NCT02269644
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Dalbavancin, Linezolid, Linezolid Placebo, Azithromycin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT01431339
View directory record Official record
Conditions
Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions
IV Dalbavancin, Vancomycin/Linezolid
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
18 Years to 85 Years
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 10, 2026, 12:09 PM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 10, 2026, 12:09 PM EDT
Completed Phase 1 Interventional

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

NCT00678106
View directory record Official record
Conditions
Bacterial Infections
Interventions
Dalbavancin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
San Diego, California • Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2009 · Synced Sep 10, 2026, 12:09 PM EDT